Summary
. Various haemovigilance systems emphasised the significance of this serious transfusion reaction during the last decade [2] [3] [4] [5] [6] [7] . Before 2004, septic reactions to platelet transfusion were estimated to occur approximately in 1 of 25,000 transfusions [8, 9] . Published contamination rates varies between 1:5,000 and 1:20,000 [10, 11] . Meanwhile different risk reduction measures have been recommended and implemented [12] [13] [14] .
In order to evaluate the effectiveness of our policy, we compared reporting rates of TTBI involving components and fatalities from 1997 to 2010 -before and after the implementation of risk-reducing measures.
Material and Methods
Reports of TTBIs from 1997 to 2010 were collected and evaluated since the implementation of the German Transfusion Act (Transfusionsgesetz; TFG). Treating physicians should send initial reports of TTBIs to the blood establishments or directly to the Paul-Ehrlich-Institute. Physicians are requested to add any missing data such as main symptoms, clinical course, identification, and categorisation of the pathogenic agent affecting the recipient as well as data of involved blood components. The confirmed TTBI back-up plasma samples or blood components from the transfused product were analysed microbiologically.
Pathogenic agent testing of the recipient blood was mostly performed in the medical institute for microbiology associated with the hospital where the recipient was treated, whereas the pathogenic agents of the donor blood were tested in the medical institute for microbiology associated with the blood establishment. In the case of university hospitals, the donor and recipient testing was performed in the same institute for microbiology. Samples were analysed by aerobic and anaerobic cultures, and bacterial identification was performed according to the general standards. A TTBI was defined by clinical criteria associated with a culture-positive residual component or a culture-positive recipient demonstrating the same bacteria as determined by, for example, antibiotic sensitivity.
In 2002 and 2008, the German Advisory Committee Blood (Arbeitskreis Blut; AK Blut) recommended two risk minimisation measures. The implementation by the blood donation establishments occurred on a voluntary basis. In order to achieve a reduction in microbial contamination of blood components, pre-donation sampling for platelet concentrates (PCs) has been recommended since June 2003 (AK Blut, opinion 27). This includes the separation and removal of at least 15 ml after venipuncture before drawing donors' blood.
Since June 2008, a limitation of the shelf life of PCs has been recommended (AK Blut, opinion 38). In order to reduce the danger of fatal transfusion reactions caused by bacterial contamination, the storage of PCs should be limited to 4 days (4 24 h), beginning at midnight of the day the blood was collected.
Statistical Analysis
The reporting rate of TTBI was calculated on the basis of confirmed TTBI and the number of transfused blood components. The figures of transfused fresh frozen plasma (FFP), PCs and red blood cell (RBC) concentrates must be reported to the PEI annually according to Section 21 of the TFG.
The difference between the reporting frequencies of TTBI was calculated using the odds ratio (with 95% confidence limits) and the exact chi- Table 1 . 
Results
Between 1997 and 2010, a total of 225 suspected cases of TTBIs were reported, and 90 cases could be confirmed based on the available laboratory data ( 13 patients (24%) with non-haematological/oncological diseases such as bleeding episodes because of trauma or duodenal ulcer surgical interventions. Pathogenic agents with low pathogenicity were found in 14 of 41 immunosuppressed patients (34%) and in 1 of 13 patients with non-haematological/ oncological diseases. Accordingly, pathogenic agents with medium to high pathogenicity were detected in 27 of 41 immunosuppressed patients (66%) and in 12 of 13 non-immunosuppressed patients.
Case Reports Case 1
Two apheresis PCs were manufactured from one donation. The apheresis PCs were irradiated 1 day after manufacture. Platelets were transfused to two oncological patients with non-Hodgkin's lymphoma or acute myeloid leukaemia on the 4th day after manufacture. Both patients developed high fever with shock symptoms during transfusion or immediately after the end of the transfusion; they had to be treated in an intensive care unit. One patient died, the other patient recovered from a severe sepsis. K. pneumoniae was found in the blood culture of both patients. The pathogenic agent could be identified by PCR testing, and agreement between strains isolated from recipients and residual components was confirmed.
reporting frequency is 1 case in 0.077 million PC units and for apheresis PCs 1 case in 0.107 per million PC units. During the same period, 43.91 million RBC concentrates were issued. 23 cases of RBC-associated TTBI and no case of RBC-associated fatalities were confirmed. This complies with a reporting frequency of 1 TTBI in 1.91 million RBC units.
24 pathogenic species of 9 genera of bacteria were detected during microbiological analyses (table 4). In 37 of the 90 cases, pathogenic agents with low pathogenicity could be identified, such as Staphylococcus epidermidis and Propionibacterium acnes, and in 53 cases agents with medium to high pathogenicity were found, such as Klebsiella pneumoniae, Serratia marcescens etc.
The most frequently identified pathogenic agents were S. epidermidis (29 cases), and Staphylococcus aureus (12 cases), which is part of the skin or airway flora. In most cases with fatal outcome (10 of 11 cases), agents with high pathogenicity were found, such as Yersinia enterocolitica, K. pneumoniae, S. marcescens, and Streptococcus pyogenes (table 4) .
Underling diseases of the recipients were reported in 54 of 90 confirmed TTBI cases. TTBIs occurred in 41 immunosuppressed (haematological/oncological) patients (76%) and in Pathogenic agents with low pathogenicity were almost only found in immunosuppressed patients, whereas agents with medium to high pathogenicity were detected also in non-immunosuppressed patients. It could be assumed that not all bacterially contaminated PC units unavoidably lead to a septic reaction. The severity of bacterial infections also seems to be influenced by the bacterial level at the time when blood components are transfused. In our reported cases with fatal outcome, 6 of 8 PCs were at the end of the shelf life when transfused, indicating a high bacterial level due to long incubation times. In order to interpret the benefit of the recommended riskreducing measures, this multifactorial aetiology must be considered. Removal of the initial 10-40 ml of blood after venipuncture before drawing donors' blood has been shown to reduce the bacterial load introduced into manufactured blood components by 40-90% [15] . The clinical significance of the pre-donation sampling was demonstrated by data from a haemovigilance program that showed a concomitant reduction in septic transfusion reactions, which were associated with skin organisms, after implementation of a 40 ml diversion pouch for whole blood-derived platelets [16] . It could be assumed that this measure is effective in reducing bacterial infections caused by blood components contaminated with skin bacteria at the time of phlebotomy, whereas infections caused by symptomatic donors with bacteraemia will not be prevented. However, the limitation of the PC shelf life focus on the prevention of severe bacterial infections due to a high bacterial level after a longer incubation time but will not be suitable to avoid infections with skin bacteria in immunosuppressed patients.
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For further reduction of TTBIs, new strategies will be discussed. More effective and reliable screening tests could provide more precise and timely results, and pathogen reduction technology might be an effective approach in the future. Scientific evaluations are needed to characterise advantages and disadvantages and to balance the benefits, risks, and costs of these strategies.
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A bacterial culture test (BacT/ALERT (bioMérieux, Nürtingen, Germany) and Pall assay (Pall GmbH, Dreieich, Germany)) was performed from the pre-donation sampling bag and did show a positive result 3 days after transfusion and 7 days after manufacture.
Case 2
A 69-year-old female patient with polycythaemia vera and blast crisis received two RBC concentrates and two pooled PCs. She developed chills, fever, tachycardia and haematuria. Blood testing revealed a rise in LDH, a decrease in haptoglobin, and an increasing coagulation disorder (disseminated intravascular coagulopathy). The patient was transferred to the intensive care unit and died within few hours because of progressive sepsis and circulatory failure. Within 8 h, bacterial culture showed a positive result, and Streptococcus agalactiae was detected in the blood samples of the recipient and the residual buffy coat. The pooled PC was transfused 4 days after manufacture.
Discussion
According to former studies, the reporting rates of TTBIs range from 1:10,000 to 1:100,000 platelet units [14] . The SHOT report 2009 confirmed a total of 22 TTBIs during the last 10 years, representing a reporting frequency of 1 case in 117,000 PC units [2] . Despite the implementation of bacterial screening testing, the American Red Cross published TTBI frequencies between 1:40,000 and 1:193,000 depending on the collecting procedure. The fatality rate was 1 in 500,000 PC units [8, 14] .
This data compares well with the German haemovigilance data. We found an overall reporting frequency of 1 TTBI in 94,000 PC units and 1 fatal outcome in 570,000 units. The frequency was higher in pooled PCs than in apheresis PCs without confirming a significant difference.
As shown in various studies, testing of PCs by aerobic and anaerobic cultures (BacT/ALERT) did not differ significantly between apheresis PCs and pooled PCs [10] [11] [12] . Bacterial contamination was found in 0.02-0.09% (1:5,000 to 1:1,100) of apheresis PCs and 0.05-0.06% (1:2,500 to 1:1,500) of pooled PCs (confirmed positive bacterial cultures).
The different frequencies of culture-positive and reported TTBIs are due to a number of factors. Awareness and attention of the treating physician is needed to interpret clinical signs of sepsis, such as fever, changes in blood pressure and rigors, as a transfusion-associated event. Bacterial levels in blood components as well as the pathogenicity of the transfused species play an important role for the manifestation of septic reactions. Finally concomitant treatment such as antibiotic treatment and underlying diseases of the recipient are important factors for the severity of a TTBI.
The interaction between transfused bacterial agents and the underlying disease of the recipient is supported by our data.
